Researchers from the United States examined the unique accurate environment of Pancreatic Ductal Adenocarcinoma, and identified a major protein that helps resist tumor treatment.
The accurate environment of the tumor is the ecosystem that includes the tumor, the surrounding immune cells, blood vessels and other tissues.
The researchers developed a new drug targeting this protein, which reduced the size of the tumor and increased the survival rate in laboratory animals.
The study was conducted by researchers from the University of Cincinnati in the United States, and its results were presented at the Special Conference of the American Cancer Research on Pancreatic Cancer, which was held on September 28 in Boston, the United States.
The results of the study were previously published in two research papers published in January and April this year, and the Yurrick Alert website was written about.
A unique environment that supports cancer
Bulk canal cancer is one of the most dangerous types of cancer, as the survival rate for 5 years is less than 10%.
Ahmed Kainak, a researcher in the study, said a doctorate degree, a co -member of the cancer center and post -PhD fellow in the Department of Blood and Oncology in the Department of Internal Medicine at the Faculty of Medicine at the University And immunotherapy.
Kainak and his colleagues identified that a proteinist is called “HSP70” (HSP70) contributes to inhibiting immunity in the tumor, and the decisive role of “HSB 70” in the cell balance was well known, but it did not receive adequate attention.
The team has developed a drug called “SaPC-Dopg” targeting cancer cells specifically by bonding with phosphatidil Sirin, a fatty substance found on the surface of the cells.
This work is based on the work of the Kynac guide, Dr. Xiayang Che, who has developed a similar drug called “Sapc-Dops”, and is currently in the second stage of clinical trials to treat lung cancer.